Business Description
Rhythm Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US76243J1051
Compare
Compare
Traded in other countries / regions
RYTM.USA1RV.GermanyRYTM.Mexico Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2017-10-05Description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 77.4 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 6.96 | |||||
| Beneish M-Score | -3.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 221.8 | |||||
| 3-Year EBITDA Growth Rate | -41.4 | |||||
| 3-Year EPS without NRI Growth Rate | -47.1 | |||||
| 3-Year FCF Growth Rate | 15.1 | |||||
| 3-Year Book Growth Rate | -60.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 63.16 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 73.33 | |||||
| 9-Day RSI | 62.48 | |||||
| 14-Day RSI | 58.12 | |||||
| 3-1 Month Momentum % | 22.66 | |||||
| 6-1 Month Momentum % | 9.56 | |||||
| 12-1 Month Momentum % | 43.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | |||||
| Quick Ratio | 3.13 | |||||
| Cash Ratio | 2.81 | |||||
| Days Inventory | 372.21 | |||||
| Days Sales Outstanding | 46.9 | |||||
| Days Payable | 211.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.5 | |||||
| Shareholder Yield % | -0.86 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.62 | |||||
| Operating Margin % | -126.13 | |||||
| Net Margin % | -123.26 | |||||
| EBITDA Margin % | -106.91 | |||||
| FCF Margin % | -82.92 | |||||
| ROE % | -116.92 | |||||
| ROA % | -47.3 | |||||
| ROIC % | -335.11 | |||||
| 3-Year ROIIC % | -286.69 | |||||
| ROC (Joel Greenblatt) % | -3929.47 | |||||
| ROCE % | -54.8 | |||||
| Moat score | 4 | |||||
| Tariff score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 30.44 | |||||
| PB Ratio | 223.07 | |||||
| Price-to-Tangible-Book | 318.67 | |||||
| EV-to-EBIT | -27.03 | |||||
| EV-to-Forward-EBIT | -26.88 | |||||
| EV-to-EBITDA | -27.32 | |||||
| EV-to-Revenue | 29.21 | |||||
| EV-to-Forward-Revenue | 22.68 | |||||
| EV-to-FCF | -35.22 | |||||
| Price-to-GF-Value | 0.87 | |||||
| Price-to-Net-Current-Asset-Value | 3346 | |||||
| Price-to-Net-Cash | 46.8 | |||||
| Earnings Yield (Greenblatt) % | -3.7 | |||||
| FCF Yield % | -2.67 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers